Skip to content
Open access

IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY

Oct 2026 · Acta Medica Nicomedia · 0 citations · 15 references

Abstract

Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs). Data regarding immunotherapy safety in elderly patients remain limited. This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients aged ≥75 years. Methods: This retrospective observational study included all consecutive cancer patients aged ≥75 years who received ICIs at our institution during the study period. All 60 eligible patients experienced at least one irAE. Demographic and clinical characteristics, treatment details, steroid requirement, and treatment continuation status were recorded. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Descriptive statistics, Pearson's chi-square tests, and Classification and Regression Tree (CRT) analysis were performed. Results: Endocrine toxicities were most frequent (18.3%), followed by renal toxicities (15.0%). Cutaneous, neurological, and pulmonary toxicities each occurred in 10.0% of patients. No significant associations were observed between irAE grade and age, sex, treatment line, ICI type, or treatment cycle at onset (p > 0.05). Steroid requirement was significantly associated with irAE grade (χ² = 24.061, p < 0.001), whereas treatment continuation status was not (χ² = 7.657, p = 0.105). Conclusion: ICIs demonstrated a spectrum of irAEs requiring clinical management in elderly patients. Demographic factors were not significantly associated with toxicity severity, whereas steroid requirement was associated with higher toxicity grades. These findings contribute to characterizing irAEs in elderly patients; however, larger prospective studies are needed to clarify immunotherapy safety in this population.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.